.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,967,208

« Back to Dashboard

Claims for Patent: 6,967,208

Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s): Pinto; Donald J. P. (Churchville, PA), Quan; Mimi L. (Yardley, PA), Orwat; Michael J. (New Hope, PA), Li; Yun-Long (Wilmington, DE), Han; Wei (Yardley, PA), Qiao; Jennifer X. (Princeton, NJ), Lam; Patrick Y. S. (Chadds Ford, PA), Koch; Stephanie L. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:10/245,122
Patent Claims: 1. A compound of Formula I: ##STR227##

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; ##STR228## ring M, including P.sub.1, P.sub.2, and M.sub.1, and M.sub.2 is substituted with 0-2 R.sup.1a and is ##STR229## ring P, including P.sub.1, P.sub.2, and P.sub.3, is P.sub.4 is --G.sub.1 --G; G is a group of Formula IIa or IIb: ##STR230## ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of: carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; ring D is substituted with 0-2 R and there are 0-3 ring double bonds; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R; alternatively, ring D is absent and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1-2 R; alternatively, ring D is absent and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1 R and with a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, wherein the 5-6 membered heterocycle is substituted with 0-1 carbonyl and 1-2 R and there are 0-3 ring double bonds; R is selected from H, C.sub.1-4 alkyl, F, Cl, Br, I, OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, OCH.sub.2 CH.sub.2 CH.sub.3, CN, C(.dbd.NR.sup.8)NR.sup.7 R.sup.9, NHC(.dbd.NR.sup.8)NR.sup.7 R.sup.9, ONHC(.dbd.NR.sup.8)NR.sup.7 R.sup.9, NR.sup.8 CH(.dbd.NR.sup.7), NH.sub.2, NH(C.sub.1-3 alkyl), N(C.sub.1-3 alkyl).sub.2, C(.dbd.NH)NH.sub.2, CH.sub.2 NH.sub.2, CH.sub.2 NH(C.sub.1-3 alkyl), CH.sub.2 N(C.sub.1-3 alkyl).sub.2, CH.sub.2 CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 NH(C.sub.1-3 alkyl), CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, (CR.sup.8 R.sup.9).sub.t C(O)H, (CR.sup.8 R.sup.9).sub.t C(O)R.sup.2c, (CR.sup.8 R.sup.9).sub.t NR.sup.7 R.sup.8, (CR.sup.8 R.sup.9).sub.t C(O)NR.sup.7 R.sup.8, (CR.sup.8 R.sup.9).sub.t NR.sup.7 C(O)R.sup.7, (CR.sup.8 R.sup.9).sub.t OR.sup.3, (CR.sup.8 R.sup.9).sub.t S(O).sub.p NR.sup.7 R.sup.8, (CR.sup.8 R.sup.9).sub.t NR.sup.7 S(O).sub.p R.sup.7, (CR.sup.8 R.sup.9).sub.t SR.sup.3, (CR.sup.8 R.sup.9).sub.t S(O)R.sup.3, (CR.sup.8 R.sup.9).sub.t S(O).sub.2 R.sup.3, and OCF.sub.3 ; alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy; A is selected from: C.sub.3-10 carbocycle substituted with 0-2 R.sup.4, B is ##STR231## provided that Z and B are attached to different atoms on A and that the A--X--N moiety forms other than a N--N--N group; Q.sub.1 is C.dbd.O; ring Q is a 6 4-8 membered monocyclic ring, wherein: 0-2 double bonds are present within the ring and the ring is substituted with 0-2 R.sup.4a ; X is absent; G.sub.1 is absent or is selected from (CR.sup.3 R.sup.3a).sub.1-5, (CR.sup.3 R.sup.3a).sub.0-2 CR.sup.3.dbd.CR.sup.3 (CR.sup.3 R.sup.3a).sub.0-2, (CR.sup.3 R.sup.3a).sub.0-2 C.ident.C(CR.sup.3 R.sup.3a).sub.0-2, (CR.sup.3 R.sup.3a).sub.u C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u C(O)O(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u OC(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u O(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u C(O)N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u OC(O)N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b C(O)O(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b C(O)N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b C(S)N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O).sub.2 (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O)N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b S(O).sub.2 (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O).sub.2 N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u N.sup.3b S(O).sub.2 N.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3e (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u C(O)(CR.sup.3 R.sup.3a).sub.u C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b (CR.sup.3 R.sup.3a).sub.u C(O)NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b C(O)(CR.sup.3 R.sup.3a).sub.u C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u C(O)(CR.sup.3 R.sup.3a).sub.u C(O)NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b C(O)(CR.sup.3 R.sup.3a).sub.u C(O)NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O)NR.sup.3b C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u C(O)NR.sup.3b S(O).sub.2 (CR.sup.3 R.sup.3a).sub.w, and (CR.sup.3 R.sup.3a).sub.u S(O).sub.2 NR.sup.3b C(O)NR.sup.3b CR.sup.3 R.sup.3a).sub.w, wherein u+w total 0, 1, 2, 3, or 4, provided that G.sub.1 does not form an N--S, NCH.sub.2 N, NCH.sub.2 O, or NCH.sub.2 S bond with either group to which it is attached; R.sup.1a, at each occurrence, is selected from H, --(CR.sup.3 R.sup.3a).sub.r --R.sup.1b, --(CR.sup.3 R.sup.3a).sub.r --CR.sup.3 R.sup.1b R.sup.1b, --(CR.sup.3 R.sup.3a).sub.r --O--(CR.sup.3 R.sup.3a).sub.r R.sup.1b, --C.sub.2-6 alkenylene-R.sup.1b, --C.sub.2-6 alkynylene-R.sup.1b, --(CR.sup.3 R.sup.3a).sub.r C(.dbd.NR.sup.1b)NR.sup.3 R.sup.1b, NR.sup.3 CR.sup.3 R.sup.3a R.sup.1c, OCR.sup.3 R.sup.3a R.sup.1c, SCR.sup.3 R.sup.3a R.sup.1c, NR.sup.3 (CR.sup.3 R.sup.3a).sub.2 (CR.sup.3 R.sup.3a).sub.t R.sup.1b, C(O)NR.sup.2 (CR.sup.3 R.sup.3a).sub.2 (CR.sup.3 R.sup.3a).sub.t R.sup.1b, CO.sub.2 (CR.sup.3 R.sup.3a).sub.2 (CR.sup.3 R.sup.3a).sub.t R.sup.1b, O(CR.sup.3 R.sup.3a).sub.2 (CR.sup.3 R.sup.3a).sub.t R.sup.1b, S(CR.sup.3 R.sup.3a).sub.2 (CR.sup.3 R.sup.3a).sub.t R.sup.1b, S(O).sub.p (CR.sup.3 R.sup.3a).sub.r R.sup.1d, O(CR.sup.3 R.sup.3a).sub.r R.sup.1d, NR.sup.3 (CR.sup.3 R.sup.3a).sub.r R.sup.1d, OC(O)NR.sup.3 (CR.sup.3 R.sup.3a).sub.r R.sup.1d, NR.sup.3 C(O)NR.sup.3 (CR.sup.3 R.sup.3a).sub.r R.sup.1d, NR.sup.3 C(O)O(CR.sup.3 R.sup.3a).sub.r R.sup.1d, and NR.sup.3 C(O)(CR.sup.3 R.sup.3a).sub.r R.sup.1d, provided that R.sup.1a forms other than an N-halo, N--S, O--O, or N--CN bond; alternatively, when two R.sup.1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-7 membered ring consisting of: carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, this ring being substituted with 0-2 R.sup.4b and 0-3 ring double bonds; R.sup.1b is selected from H, C.sub.1-3 alkyl, F, Cl, Br, I, --CN, --NO.sub.2, --CHO, (CF.sub.2).sub.r CF.sub.3, (CR.sup.3 R.sup.3a).sub.r OR.sup.2, NR.sup.2 R.sup.2a, C(O)R.sup.2b, CO.sub.2 R.sup.2b, OC(O)R.sup.2, (CF.sub.2).sub.r CO.sub.2 R.sup.2a, S(O).sub.p R.sup.2b, NR.sup.2 (CH.sub.2).sub.r OR.sup.2, C(.dbd.NR.sup.2c)NR.sup.2 R.sup.2a, NR.sup.2 C(O)R.sup.2b, NR.sup.2c (O)NHR.sup.2, NR.sup.2 C(O).sub.2 R.sup.2a, OC(O)NR.sup.2 R.sup.2a, C(O)NR.sup.2 R.sup.2a, C(O)NR.sup.2 (CH.sub.2).sub.r OR.sup.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 R.sup.2, C(O)NR.sup.2 SO.sub.2 R.sup.2, C.sub.3-6 carbocycle substituted with 0-2 R.sup.4b, and 5-10 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b, provided that R.sup.1b forms other than an O--O, N-halo, N--S, or N--CN bond; R.sup.1c is selected from H, CH(CH.sub.2 OR.sup.2).sub.2, C(O)R.sup.2c, C(O)NR.sup.2 R.sup.2a, S(O)R.sup.2, S(O).sub.2 R.sup.2, and SO.sub.2 NR.sup.2 R.sup.2a ; R.sup.1d is selected from C.sub.3-6 carbocycle substituted with 0-2 R.sup.4b and 5-10 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b, provided that R.sup.1d forms other than an N--S bond; R.sup.2, at each occurrence, is selected from H, CF.sub.3, C.sub.1-6 alkyl, benzyl, --(CH.sub.2).sub.r --C.sub.3-10 carbocycle substituted with 0-2 R.sup.4b, and --(CH.sub.2).sub.r -5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CF.sub.3, C.sub.1-6 alkyl, benzyl, --(CH.sub.2).sub.r --C.sub.3-10 carbocycle substituted with 0-2 R.sup.4b, and --(CH.sub.2).sub.r -5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R.sup.4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.2b, at each occurrence, is selected from CF.sub.3, C.sub.1-4 alkoxy substituted with 0-2 R.sup.4b, C.sub.1-6 alkyl substituted with 0-2 R.sup.4b, --(CH.sub.2).sub.r --C.sub.3-10 carbocycle substituted with 0-2 R.sup.4b, and --(CH.sub.2).sub.r -5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.2c, at each occurrence, is selected from CF.sub.3, OH, C.sub.1-4 alkoxy, C.sub.1-6 alkyl, --(CH.sub.2).sub.r --C.sub.3-10 carbocycle substituted with 0-2 R.sup.4b, and --(CH.sub.2).sub.r -5-10 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.3, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl, and phenyl; R.sup.3a, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl, and phenyl; alternatively, R.sup.3 and R.sup.3a, together with the nitrogen atom to which they are attached, combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring consisting of: carbon atoms, the nitrogen atom to which R.sup.3 and R.sup.3a are attached, and 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.3b, at each occurrence, is selected from H, C.sub.1-6 alkyl substituted with 0-2 R.sup.1a, C.sub.2-6 alkenyl substituted with 0-2 R.sup.1a, C.sub.2-6 alkynyl substituted with 0-2 R.sup.1a, --(C.sub.0-4 alkyl)-5-10 membered carbocycle substituted with 0-3 R.sup.1a, and --(C.sub.0-4 alkyl)-5-10 membered heterocycle substituted with 0-3 R.sup.1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.3c, at each occurrence, is selected from CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl, and phenyl; R.sup.3d, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C.sub.1-4 alkyl-phenyl, and C(.dbd.O)R.sup.3c ; R.sup.3e, at each occurrence, is selected from H, SO.sub.2 NHR.sup.3, SO.sub.2 NR.sup.3 R.sup.3, C(O)R.sup.3, C(O)NHR.sup.3, C(O)OR.sup.3f, S(O)R.sup.3f, S(O).sub.2 R.sup.3f, C.sub.1-6 alkyl substituted with 0-2 R.sup.1a, C.sub.2-6 alkenyl substituted with 0-2 R.sup.1a, C.sub.2-6 alkynyl substituted with 0-2 R.sup.1a, --(C.sub.0-4 alkyl)-5-10 membered carbocycle substituted with 0-3 R.sup.1a, and --(C.sub.0-4 alkyl)-5-10 membered heterocycle substituted with 0-3 R.sup.1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.3f, at each occurrence, is selected from: C.sub.1-6 alkyl substituted with 0-2 R.sup.1a, C.sub.2-6 alkenyl substituted with 0-2 R.sup.1a, C.sub.2-6 alkynyl substituted with 0-2 R.sup.1a, --(C.sub.0-4 alkyl)-5-10 membered carbocycle substituted with 0-3 R.sup.1a, and --(C.sub.0-4 alkyl)-5-10 membered heterocycle substituted with 0-3 R.sup.1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.4, at each occurrence, is selected from H, .dbd.O, (CR.sup.3 R.sup.3a).sub.r OR.sup.2, F, Cl, Br, I, C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a).sub.r CN, (CR.sup.3 R.sup.3a).sub.r NO.sub.2, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(O)R.sup.2c, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 C(O)R.sup.2b, (CR.sup.3 R.sup.3a).sub.r C(O)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 C(O)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(.dbd.NS(O).sub.2 R.sup.5)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(O)NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r SO.sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 SO.sub.2 R.sup.5, (CR.sup.3 R.sup.3a).sub.r S(O).sub.p R.sup.5a, (CR.sup.3 R.sup.3a).sub.r (CF.sub.2).sub.r CF.sub.3, NHCH.sub.2 R.sup.1c, OCH.sub.2 R.sup.1c, SCH.sub.2 R.sup.1c, NH(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, O(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, S(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, (CR.sup.3 R.sup.3a).sub.r -5-6 membered carbocycle substituted with 0-1 R.sup.5, and a (CR.sup.3 R.sup.3a).sub.r -5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5 ; R.sup.4a, at each occurrence, is selected from H, .dbd.O, (CR.sup.3 R.sup.3a).sub.r OR.sup.2, (CR.sup.3 R.sup.3a).sub.r F, (CR.sup.3 R.sup.3a).sub.r Br, (CR.sup.3 R.sup.3a).sub.r Cl, C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a).sub.r CN, (CR.sup.3 R.sup.3a).sub.r NO.sub.2, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(O)R.sup.2c, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 C(O)R.sup.2b, (CR.sup.3 R.sup.3a).sub.r C(O)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r N.dbd.CHOR.sup.3, (CR.sup.3 R.sup.3a).sub.r C(O)NH(CH.sub.2).sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 C(O)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r SO.sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a).sub.r C(O)NHSO.sub.2 --C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a)NR.sup.2 SO.sub.2 R.sup.5, (CR.sup.3 R.sup.3a).sub.r S(O).sub.p R.sup.5a, (CR.sup.3 R.sup.3a).sub.r (CF.sub.2).sub.r CF.sub.3, (CR.sup.3 R.sup.3a).sub.r -5-6 membered carbocycle substituted with 0-1 R.sup.5, and a (CR.sup.3 R.sup.3a).sub.r -5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.3, (CH.sub.2).sub.r F, (CH.sub.2).sub.r Cl, (CH.sub.2).sub.r Br,

(CH.sub.2).sub.r I, C.sub.1-4 alkyl, (CH.sub.2).sub.r CN, (CH.sub.2).sub.r NO.sub.2, (CH.sub.2).sub.r NR.sup.3 R.sup.3a, (CH.sub.2).sub.r C(O)R.sup.3, (CH.sub.2).sub.r C(O)OR.sup.3c, (CH.sub.2).sub.r NR.sup.3 C(O)R.sup.3a, (CH.sub.2).sub.r --C(O)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 C(O)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r --C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r SO.sub.2 NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 CF.sub.3, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 -phenyl, (CH.sub.2).sub.r S(O).sub.p CF.sub.3, (CH.sub.2).sub.r S(O).sub.p --C.sub.1-4 alkyl, (CH.sub.2).sub.r S(O).sub.p -phenyl, and (CH.sub.2).sub.r (CF.sub.2).sub.r CF.sub.3 ; R.sup.4c, at each occurrence, is selected from H, C.sub.1-4 alkyl (CR.sup.3 R.sup.3a).sub.r1 OR.sup.2, (CR.sup.3 R.sup.3a).sub.r1 F, (CR.sup.3 R.sup.3a).sub.r1 Br, (CR.sup.3 R.sup.3a).sub.r1 Cl, (CR.sup.3 R.sup.3a).sub.r1 CN, (CR.sup.3 R.sup.3a).sub.r1 NO.sub.2, (CR.sup.3 R.sup.3a).sub.r1 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r C(O)R.sup.2c, (CR.sup.3 R.sup.3a).sub.r1 NR.sup.2 C(O)R.sup.2b, (CR.sup.3 R.sup.3a).sub.r C(O)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r1 N.dbd.CHOR.sup.3, (CR.sup.3 R.sup.3a).sub.r C(O)NH(CH.sub.2).sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r1 NR.sup.2 C(O)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r1 C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r1 NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r SO.sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r1 NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, (CR.sup.3 R.sup.3a).sub.r1 NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a).sub.r C(O)NHSO.sub.2 --C.sub.1-4 alkyl, (CR.sup.3 R.sup.3a).sub.r1 NR.sup.2 SO.sub.2 R.sup.5, (CR.sup.3 R.sup.3a).sub.r S(O).sub.p R.sup.5a, (CR.sup.3 R.sup.3a).sub.r (CF.sub.2).sub.r CF.sub.3, (CR.sup.3 R.sup.3a).sub.r -5-6 membered carbocycle substituted with 0-1 R.sup.5, and a (CR.sup.3 R.sup.3a).sub.r -5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5 ; R.sup.5, at each occurrence, is selected from H, C.sub.1-6 alkyl, .dbd.O, (CH.sub.2).sub.r OR.sup.3, F, Cl, Br, I, --CN, NO.sub.2,(CH.sub.2).sub.r NR.sup.3 R.sup.3a, (CH.sub.2).sub.r C(O)R.sup.3, (CH.sub.2).sub.r C(O)OR.sup.3c, (CH.sub.2).sub.r NR.sup.3 C(O)R.sup.3a,(CH.sub.2).sub.r C(O)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 C(O)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r CH(.dbd.NOR.sup.3d), (CH.sub.2).sub.r C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, (CH.sub.2).sub.r SO.sub.2 NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 C.sub.1-4 alkyl, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 CF.sub.3, (CH.sub.2).sub.r NR.sup.3 SO.sub.2 -phenyl, (CH.sub.2).sub.r S(O).sub.p CF.sub.3, (CH.sub.2).sub.r S(O).sub.p --C.sub.1-4 alkyl, (CH.sub.2).sub.r S(O).sub.p -phenyl, (CF.sub.2).sub.r CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; R.sup.5a, at each occurrence, is selected from C.sub.1-6 alkyl, (CH.sub.2).sub.r OR.sup.3, (CH.sub.2).sub.r NR.sup.3 R.sup.3a, (CH.sub.2).sub.r C(O)R.sup.3, (CH.sub.2).sub.r C(O)OR.sup.3c, (CH.sub.2).sub.r NR.sup.3 C(O)R.sup.3a, (CH.sub.2).sub.r C(O)NR.sup.3 R.sup.3a, (CF.sub.2).sub.r CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6, provided that R.sup.5a does not form a S--N or S(O).sub.p --C(O) bond; R.sup.6, at each occurrence, is selected from H, OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, and NR.sup.2 SO.sub.2 C.sub.1-4 alkyl; R.sup.7, at each occurrence, is selected from H, OH, C.sub.1-6 alkyl, C.sub.1-6 alkyl-C(O)--, C.sub.1-6 alkyl-O--, (CH.sub.2).sub.n -phenyl, C.sub.1-4 alkyl-OC(O)--, C.sub.6-10 aryl-O--, C.sub.6-10 aryl-OC(O)--, C.sub.6-10 aryl-CH.sub.2 --C(O)--, C.sub.1-4 alkyl-C(O)O--C.sub.1-4 alkyl-OC(O)--, C.sub.6-10 aryl-C(O)O--C.sub.1-4 alkyl-OC(O)--, C.sub.1-6 alkyl-NH.sub.2 --C(O)--, phenyl-NH.sub.2 --C(O)--, and phenyl-C.sub.1-4 alkyl-C(O)--; R.sup.8, at each occurrence, is selected from H, C.sub.1-6 alkyl, and (CH.sub.2).sub.n -phenyl; alternatively, R.sup.7 and R.sup.8, when attached to the same nitrogen, combine to form a 5-10 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.9, at each occurrence, is selected from H, C.sub.1-6 alkyl, and (CH.sub.2).sub.n -phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3; p, at each occurrence, is selected from 0,1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, 4, 5, and 6; r1, at each occurrence, is selected from 1, 2, 3, 4, 5, and 6; t, at each occurrence, is selected from 0, 1, 2, and 3.

2. A compound according to claim 1, wherein: G is a group of Formula IIa or IIb: ##STR232## ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of: carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; ring D is substituted with 0-2 R and there are 0-3 ring double bonds; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R; alternatively, ring D is absent, and ring E is selected from phenyl, pyridyl, pyrimidyl, and thienyl, and ring E is substituted with 1-2 R; alternatively, ring D is absent, ring E is selected from phenyl, pyridyl, and thienyl, and ring E is substituted with 1 R and substituted with a 5 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, wherein the 5 membered heterocycle is substituted with 0-1 carbonyl and 1-2 R and there are 0-3 ring double bonds; R is selected from H, C.sub.1-4 alkyl, F, Cl, OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, CN, C(.dbd.NH)NH.sub.2, C(.dbd.NH)NHOH, C(.dbd.NH)NHOCH.sub.3, NH.sub.2, NH(C.sub.1-3 alkyl), N(C.sub.1-3 alkyl).sub.2, C(.dbd.NH)NH.sub.2, CH.sub.2 NH.sub.2, CH.sub.2 NH(C.sub.1-3 alkyl), CH.sub.2 N(C.sub.1-3 alkyl).sub.2, (CR.sup.8 R.sup.9).sub.t NR.sup.7 R.sup.8, C(O)NR.sup.7 R.sup.8, CH.sub.2 C(O)NR.sup.7 R.sup.8, S(O).sub.p NR.sup.7 R.sup.8, CH.sub.2 S(O).sub.p NR.sup.7 R.sup.8, SO.sub.2 R.sup.3, and OCF.sub.3 ; alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy; A is selected from: C.sub.5-10 carbocycle substituted with 0-2 R.sup.4 ; R.sup.1a is selected from H, --(CH.sub.2).sub.r --R.sup.1b, --(CH(CH.sub.3)).sub.r --R.sup.1b, --(C(CH.sub.3).sub.2).sub.r --R.sup.1b, NHCH.sub.2 R.sup.1c, OCH.sub.2 R.sup.1c, SCH.sub.2 R.sup.1c, NH(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, and O(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1b, provided that R.sup.1a forms other than an N-halo, N--S, or N--CN bond; alternatively, when two R.sup.1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-7 membered ring consisting of: carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, this ring being substituted with 0-2 R.sup.4b and 0-3 ring double bonds; R.sup.1b is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, F, Cl, Br, I, --CN, --CHO, CF.sub.3, OR.sup.2, NR.sup.2 R.sup.2a, C(O)R.sup.2b, CO.sub.2 R.sup.2b, OC(O)R.sup.2, CO.sub.2 R.sup.2a, S(O).sub.p R.sup.2, NR.sup.2 (CH.sub.2).sub.r OR.sup.2, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)NHR.sup.2, NR.sup.2 C(O).sub.2 R.sup.2a, OC(O)NR.sup.2 R.sup.2a, C(O)NR.sup.2 R.sup.2a, C(O)NR.sup.2 (CH.sub.2).sub.r OR.sup.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 R.sup.2, C.sub.5-6 carbocycle substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b, provided that R.sup.1b forms other than an O--O, N-halo, N--S, or N--CN bond; R.sup.1c is selected from H, CH(CH.sub.2 OR.sup.2).sub.2, C(O)R.sup.2c, C(O)NR.sup.2 R.sup.2a, S(O)R.sup.2, S(O).sub.2 R.sup.2, and SO.sub.2 NR.sup.2 R.sup.2a ; R.sup.2, at each occurrence, is selected from H, CF.sub.3, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl, C.sub.5-6 carbocycle substituted with 0-2 R.sup.4b, a C.sub.5-6 carbocyclic-CH.sub.2 -group substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CF.sub.3, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl, C.sub.5-6 carbocycle substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R.sup.4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.2b, at each occurrence, is selected from CF.sub.3, C.sub.1-4 alkoxy, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl, C.sub.5-6 carbocycle substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.2c, at each occurrence, is selected from CF.sub.3, OH, C.sub.1-4 alkoxy, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, benzyl C.sub.5-6 carbocycle substituted with 0-2 R.sup.4b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.3, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, and phenyl; R.sup.3a, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, and phenyl; alternatively, R.sup.3 and R.sup.3a, together with the nitrogen atom to which they are attached, combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring consisting of: carbon atoms and the nitrogen atom to which R.sup.3 and R.sup.3a are attached; R.sup.3c, at each occurrence, is selected from CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl phenyl; R.sup.3d, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 -phenyl, CH.sub.2 CH.sub.2 -phenyl, and C(.dbd.O)R.sup.3c ; R.sup.4, at each occurrence, is selected from H, .dbd.O, OR.sup.2, CH.sub.2 OR.sup.2, (CH.sub.2).sub.2 OR.sup.2, F, Cl, Br, I, C.sub.1-4 alkyl, --CN, NO.sub.2, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, (CH.sub.2).sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, S(O).sub.p R.sup.5a, CF.sub.3, CF.sub.2 CF.sub.3, 5-6 membered carbocycle substituted with 0-1 R.sup.5, and a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5 ; R.sup.4a, at each occurrence, is selected from H, .dbd.O, CH.sub.2 OR.sup.2, OR.sup.2, CH.sub.2 F, F, CH.sub.2 Br, Br, CH.sub.2 Cl, Cl, C.sub.1-4 alkyl, CH.sub.2 --CN, --CN, CH.sub.2 NO.sub.2, NO.sub.2, CH.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 R.sup.2a, CH.sub.2 --C(O)R.sup.2c, C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, (CH.sub.2).sub.r C(O)NR.sup.2 R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, (CH.sub.2).sub.r SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.2 SO.sub.2 R.sup.5, (CH.sub.2).sub.r S(O).sub.p R.sup.5a, CH.sub.2 CF.sub.3, CF.sub.3, CH.sub.2 -5-6 membered carbocycle substituted with 0-1 R.sup.5, 5-6 membered carbocycle substituted with 0-1 R.sup.5, and a CH.sub.2 -5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, --CN, NO.sub.2, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, CH.sub.2 --C(O)R.sup.3, C(O)OR.sup.3c, CH.sub.2 C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, CH.sub.2 NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, CH.sub.2 C(O)NR.sup.3 R.sup.3a, NR.sup.3 C(O)NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 C(O)NR.sup.3 R.sup.3a, C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, CH.sub.2 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, CH.sub.2 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, CH.sub.2 NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl NR.sup.3 SO.sub.2 CF.sub.3, CH.sub.2 NR.sup.3 SO.sub.2 CF.sub.3, NR.sup.3 SO.sub.2 -phenyl, CH.sub.2 NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, CH.sub.2 S(O).sub.p CF.sub.3, S(O).sub.p --C.sub.1-4 alkyl, CH.sub.2 S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, CH.sub.2 S(O).sub.p -phenyl, CF.sub.3, and CH.sub.2 --CF.sub.3 ; R.sup.4c, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, CH.sub.2 OR.sup.2, CH.sub.2 F, CH.sub.2 Br, CH.sub.2 Cl, CH.sub.2 CN, CH.sub.2 NO.sub.2, CH.sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2c, CH.sub.2 C(O)R.sup.2c, CH.sub.2 NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, CH.sub.2 C(O)NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, CH.sub.2 SO.sub.2 NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, C(O)NHSO.sub.2 --C.sub.1-4 alkyl, CH.sub.2 C(O)NHSO.sub.2 --C.sub.1-4 alkyl, CH.sub.2 NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.5a, CH.sub.2 S(O).sub.p R.sup.5a, CF.sub.3, CH.sub.2 CF.sub.3, 5-6 membered carbocycle substituted with 0-1 R.sup.5, CH.sub.2 -5-6 membered carbocycle substituted with 0-1 R.sup.5, 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5, and a CH.sub.2 -5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.5 ; R.sup.5, at each occurrence, is selected from H, .dbd.O, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, --CN, NO.sub.2, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, CH.sub.2 C(O)R.sup.3, C(O)OR.sup.3c, CH.sub.2 C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, NR.sup.3 C(O)NR.sup.3 R.sup.3a, CH(.dbd.NOR.sup.3d), C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 CF.sub.3, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; and, R.sup.6, at each occurrence, is selected from H, OH, OR.sup.2, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, CN, NO.sub.2, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2b, CH.sub.2 C(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, and NR.sup.2 SO.sub.2 C.sub.1-4 alkyl.

3. A compound according to claim 2, wherein; G is selected from the group: ##STR233## ##STR234## ##STR235## ##STR236## ##STR237## ##STR238## ##STR239## ##STR240## ##STR241## G.sub.1 is absent or is selected from (CR.sup.3 R.sup.3a).sub.1-3, (CR.sup.3 R.sup.3a).sub.u C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u O(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u C(O)NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b C(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b C(O)(CR.sup.3 R.sup.3a).sub.u C(O)NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O)(CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O).sub.2 (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u S(O)NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, (CR.sup.3 R.sup.3a).sub.u NR.sup.3b S(O).sub.2 (CR.sup.3 R.sup.3a).sub.w, and (CR.sup.3 R.sup.3a).sub.u S(O).sub.2 NR.sup.3b (CR.sup.3 R.sup.3a).sub.w, wherein u+w total 0, 1, or 2, provided that G.sub.1 does not form a N--S, NCH.sub.2 N, NCH.sub.2 O, or NCH.sub.2 S bond with either group to which it is attached; A is phenyl substituted with 0-2 R.sup.4 ; R.sup.1a is selected from H, R.sup.1b, CH(CH.sub.3)R.sup.1b, C(CH.sub.3).sub.2 R.sup.1b, CH.sub.2 R.sup.1b, and CH.sub.2 CH.sub.2 R.sup.1b, provided that R.sup.1a forms other than an N-halo, N--S, or N--CN bond; alternatively, when two R.sup.1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-6 membered ring consisting of: carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, this ring being substituted with 0-2 R.sup.4b and 0-3 ring double bonds; R.sup.1b is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, F, Cl, Br, --CN, --CHO, CF.sub.3, OR.sup.2, NR.sup.2 R.sup.2a, C(O)R.sup.2b, CO.sub.2 R.sup.2b, OC(O)R.sup.2, CO.sub.2 R.sup.2a, S(O).sub.p R.sup.2, NR.sup.2 (CH.sub.2).sub.r OR.sup.2, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 R.sup.2, phenyl substituted with 0-2 R.sup.4b, and 5-6 membered aromatic heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b, provided that R.sup.1b forms other than an O--O, N-halo, N--S, or N--CN bond; R.sup.2, at each occurrence, is selected from H, CF.sub.3, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, phenyl substituted with 0-2 R.sup.4b, a benzyl substituted with 0-2 R.sup.4b, and a 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CF.sub.3, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, phenyl substituted with 0-2 R.sup.4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 hetero atoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R.sup.4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.2b, at each occurrence, is selected from CF.sub.3, C.sub.1-4 alkoxy, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, phenyl substituted with 0-2 R.sup.4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.2c, at each occurrence, is selected from CF.sub.3, OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH.sub.2 CH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, phenyl substituted with 0-2 R.sup.4b, and 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b ; R.sup.4, at each occurrence, is selected from H, CH.sub.2 OR.sup.2, (CH.sub.2).sub.2 OR.sup.2, OR.sup.2, F, Cl, Br, I, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, --CN, NO.sub.2, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, (CH.sub.2).sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, CF.sub.3, and CF.sub.2 CF.sub.3 ; R.sup.4a at each occurrence, is selected from H, .dbd.O, CH.sub.2 OR.sup.2, OR.sup.2, F, Br, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, --CN, NO.sub.2, CH.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 R.sup.2a, C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, and --CF.sub.3 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, --CN, NO.sub.2, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, CH.sub.2 --C(O)R.sup.3, C(O)OR.sup.3c, CH.sub.2 --C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, CH.sub.2 NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, CH.sub.2 --C(O)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, CH.sub.2 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.14 alkyl, CH.sub.2 NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 -phenyl, CH.sub.2 NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, CH.sub.2 S(O).sub.p CF.sub.3, S(O).sub.p --C.sub.1-4 alkyl, CH.sub.2 S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, CH.sub.2 S(O).sub.p -phenyl, and CF.sub.3 ; R.sup.4c, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, CH.sub.2 OR.sup.2, CH.sub.2 F, CH.sub.2 Br, CH.sub.2 Cl, CH.sub.2 CN, CH.sub.2 NO.sub.2, CH.sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.c, CH.sub.2 C(O)R.sup.2c, CH.sub.2 NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, CH.sub.2 C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, CH.sub.2 SO.sub.2 NR.sup.2 R.sup.2a, S(O).sub.p R.sup.5a, CH.sub.2 S(O).sub.p R.sup.5a, CF.sub.3, phenyl substituted with 0-1 R.sup.5, and benzyl substituted with 0-1 R.sup.5 ; R.sup.5, at each occurrence, is selected from H, .dbd.O, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, --CN, NO.sub.2, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, CH.sub.2 C(O)R.sup.3, C(O)OR.sup.3c, CH.sub.2 C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 CF.sub.3, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; and, R.sup.6, at each occurrence, is selected from H, OH, OR.sup.2, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, --CN, NO.sub.2, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2b, CH.sub.2 C(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, SO.sub.2 NR.sup.2 R.sup.2a, and NR.sup.2 SO.sub.2 C.sub.1-4 alkyl.

4. A compound according to claim 3, wherein; G is selected from the group: ##STR242## ##STR243## ##STR244## ##STR245## ##STR246## G.sub.1 is absent or is selected from CH.sub.2, CH.sub.2 CH.sub.2, CH.sub.2 O, OCH.sub.2, NH, CH.sub.2 NH, NHCH.sub.2, CH.sub.2 C(O), C(O)CH.sub.2, C(O)NH, NHC(O), CH.sub.2 S(O).sub.2, S(O).sub.2 (CH.sub.2), SO.sub.2 NH, and NHSO.sub.2, provided that G.sub.1 does not form a N--S, NCH.sub.2 N, NCH.sub.2 O, or NCH.sub.2 S bond with either group to which it is attached; R.sup.1a is selected from H, R.sup.1b, C(CH.sub.3).sub.2 R.sup.1b, and CH.sub.2 R.sup.1b, provided that R.sup.1a forms other than an N-halo, N--S, or N--CN bond; R.sup.1b is selected from CH.sub.3, CH.sub.2 CH.sub.3, F, Cl, Br, --CN, CF.sub.3, OR.sup.2, NR.sup.2 R.sup.2a, C(O)R.sup.2b, CO.sub.2 R.sup.2b, CO.sub.2 R.sup.2a, S(O).sub.p R.sup.2, C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 R.sup.2, and 5-6 membered aromatic heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-2 R.sup.4b, provided that R.sup.1b forms other than an O--O, N-halo, N--S, or N--CN bond; R.sup.2, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, phenyl substituted with 0-1 R.sup.4b, benzyl substituted with 0-1 R.sup.4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, phenyl substituted with 0-1 R.sup.4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.4b ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-1 R.sup.4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.2b, at each occurrence, is selected from OCH.sub.3, OCH.sub.2 CH.sub.3, OCH.sub.2 CH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, phenyl substituted with 0-1 R.sup.4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.4b ; R.sup.2c, at each occurrence, is selected from OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH.sub.2 CH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, benzyl, phenyl substituted with 0-1 R.sup.4b, and 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.4b ; R.sup.4, at each occurrence, is selected from OH, OR.sup.2, CH.sub.2 OR.sup.2, (CH.sub.2).sub.2 OR.sup.2, F, Br, Cl, I, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, (CH.sub.2).sub.2 NR.sup.2 R.sup.2a, CF.sub.3, and CF.sub.2 CF.sub.3 ; R.sup.4a, at each occurrence, is selected from H, .dbd.O, CH.sub.2 OR.sup.2, OR.sup.2, F, Br, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, C(CH.sub.3).sub.3, CH.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 R.sup.2a, C(O)R.sup.2c, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, and CF.sub.3 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, --CN, NO.sub.2, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, and CF.sub.3 ; R.sup.4c, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, phenyl substituted with 0-1 R.sup.5, and benzyl substituted with 0-1 R.sup.5 ; R.sup.5, at each occurrence, is selected from H, .dbd.O, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, --CN, NO.sub.2, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p --C.sub.1-4 alkyl, S(O).sub.p -phenyl, CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; and, R.sup.6, at each occurrence, is selected from H, OH, OR.sup.2, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, --CN, NO.sub.2, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2b, CH.sub.2 C(O)R.sup.2b, CH.sub.2 c(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, and SO.sub.2 NR.sup.2 R.sup.2a.

5. A compound according to claim 4, wherein; G is selected from: ##STR247## ##STR248## ##STR249## A is selected from the group: phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; B is attached to a different atom on A than M and is selected from the group: ##STR250## R.sup.1a is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 F, CH.sub.2 Cl, Br, CH.sub.2 Br, --CN, CH.sub.2 CN, CF.sub.3, CH.sub.2 CF.sub.3, OCH.sub.3, CH.sub.2 OH, C(CH.sub.3).sub.2 OH, CH.sub.2 OCH.sub.3, NH.sub.2, CH.sub.2 NH.sub.2, NHCH.sub.3, CH.sub.2 NHCH.sub.3, N(CH.sub.3).sub.2, CH.sub.2 N(CH.sub.3).sub.2, CO.sub.2 H, COCH.sub.3, CO.sub.2 CH.sub.3, CH.sub.2 CO.sub.2 CH.sub.3, SCH.sub.3, CH.sub.2 SCH.sub.3, S(O)CH.sub.3, CH.sub.2 S(O)CH.sub.3, S(O).sub.2 CH.sub.3, CH.sub.2 S(O).sub.2 CH.sub.3, C(O)NH.sub.2, CH.sub.2 C(O)NH.sub.2, SO.sub.2 NH.sub.2, CH.sub.2 SO.sub.2 NH.sub.2, NHSO.sub.2 CH.sub.3, CH.sub.2 NHSO.sub.2 CH.sub.3, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-2-yl-N-oxide, pyridin-3-yl-N-oxide, pyridin-4-yl-N-oxide, imidazol-1-yl, CH.sub.2 -imidazol-1-yl, 4-methyl-oxazol-2-yl, 4-N,N-dimethylaminomethyl-oxazol-2-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, CH.sub.2 -1,2,3,4-tetrazol-1-yl, and CH.sub.2 -1,2,3,4-tetrazol-5-yl, provided that R.sup.1a forms other than an N-halo, N--S, or N--CN bond; R.sup.2, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, phenyl substituted with 0-1 R.sup.4b, benzyl substituted with 0-1 R.sup.4b, and 5 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O).sub.p, and substituted with 0-1 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CH.sub.3, and CH.sub.2 CH.sub.3 ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-1 R.sup.4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O).sub.p ; R.sup.2b, at each occurrence, is selected from OCH.sub.3, OCH.sub.2 CH.sub.3, CH.sub.3, and CH.sub.2 CH.sub.3 ; R.sup.2c, at each occurrence, is selected from OH, OCH.sub.3, OCH.sub.2 CH.sub.3, CH.sub.3, and CH.sub.2 CH.sub.3 ; R.sup.4a, at each occurrence, is selected from H, .dbd.O, CH.sub.3, CH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3, CH.sub.2 CH(CH.sub.3).sub.2, CH(CH.sub.3)CH.sub.2 CH.sub.3, and C(CH.sub.3).sub.3 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.2 CH.sub.3, S(O).sub.2 -phenyl, and CF.sub.3 ; R.sup.5, at each occurrence, is selected from H, .dbd.O, CH.sub.3, CH.sub.2 CH.sub.3, OR.sup.3, CH.sub.2 OR.sup.3, F, Cl, NR.sup.3 R.sup.3a, CH.sub.2 NR.sup.3 R.sup.3a, C(O)R.sup.3, C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.2 --CH.sub.3, S(O).sub.p -phenyl, CF.sub.3, phenyl substituted with 0-2 R.sup.6, naphthyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; and, R.sup.6, at each occurrence, is selected from H, OH, OR.sup.2, F, Cl, CH.sub.3, CH.sub.2 CH.sub.3, NR.sup.2 R.sup.2a, CH.sub.2 NR.sup.2 R.sup.2a, C(O)R.sup.2b, CH.sub.2 C(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, and SO.sub.2 NR.sup.2 R.sup.2 a.

6. A compound according to claim 5, wherein the compound is ##STR251## P.sub.4 is --G; G is selected from: ##STR252## ##STR253## and, A--B is selected from: ##STR254##

7. A compound according to claim 6, wherein: A--B is selected from: ##STR255##

8. A compound according to claim 1, wherein the compound is selected from the group: 3-methoxy-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tet rahydro-7-H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-3-[(methylamino)methyl]-6-[4-(2-oxo-1-piperidinyl)pheny l]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(3-chloro-4-fluorophenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluorom ethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one; 1-[3-(aminomethyl)-4-fluorophenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(tri fluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one; 1-(3-amino-1,2-benzisoxazol-5-yl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trif luoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1 ,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahy dro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(1H-tetraazol-5-yl) -1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl-4,5,6,7-tetrahyd ro-1H-pyrazole-[3,4-c]pyridine-3-carboxamide; 3-bromo-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetra hydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(4-pyridinyl)-1,4,5 ,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(4-pyridinyl-N-oxid e)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(3-pyridinyl)-1,4,5 ,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(3-pyridinyl-N-oxid e)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(2-pyridinyl)-1,4,5 ,6-tetrahydro-7H-pyrazolo[3,4-c]-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7H -pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-methoxyphenyl)-3-(methylsulfonyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1, 4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-(4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(2-pyridinyl)-1,4 ,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-[3-(aminomethyl)phenyl]-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromet hyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 3-[7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-4,5,6,7-tetr ahydro-1H-pyrazolo[3,4-c]pyridin-1-yl]benzamide; 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahyd ro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahy dro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(3-chlorophenyl)-N,N-dimethyl-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5 ,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(3-chloro-4-fluorophenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7 -tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile; 1-(3-amino-1H-indazol-5-yl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7 -tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(3-amino-1,2-benzisoxazol-5-yl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4 ,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(2,3-dihydro-1H-indol-6-yl)-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(triflu oromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(2,3-dihydro-1H-indol-6-yl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluor omethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(2,3-dihydro-1H-isoindol-5-yl)-6-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-trif luoromethyl-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxyphenyl)-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-3-(2-pyrrolidin-1-y lmethyl-phenyl)-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetr ahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 1-(4-methoxyphenyl)-N,N-dimethyl-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; N-({1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-t etrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl}carbonyl)methanesulfonamide; 1-(4-hydroxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetr ahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-methoxyphenyl)-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(1H-tetraazol-5-y l)-1,4,5,6,-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; 3-{4-[dimethylamino)methyl]-1,3-oxazol-2-yl}-1-(4-methoxyphenyl)-6-[4-(2-ox o-1(2H)-pyridinyl)phenyl]-1,4,5,6,-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-o ne; 3-{4-[dimethylamino)methyl]-1,3-oxazol-2-yl }-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6,-tetrahydr o-7H-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxy-phenyl)-3-(4-methyl-oxazol-2-yl)-6-[4-(2-oxo-piperidin-1-yl)-p henyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxy-phenyl)-3-(4-methyl-oxazol-2-yl)-6-[4-(2-oxo-2H-1-pyridin-1-yl )-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 3-acetyl-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6- tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 3-(4,5-dihydro-1H-imidazol-2-yl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridi n-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxy-phenyl)-3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-6-[4-(2-oxo- piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxy-phenyl)-3-(1-methyl-1H-imidazol-2-yl)-6-[4-(2-oxo-piperidin-1- yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 1-(4-methoxy-phenyl)-3-methyl-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-t etrahydro-pyrazolo[3,4-c]pyridin-7-one; 3-hydroxymethyl-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1 ,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-piperidin-1-y l)-phenyl]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one; 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1- yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 2-dimethylamino-N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phen yl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}-N-methylacetam ide; 2-dimethylamino-N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-p henyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}acetamide; N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetr ahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}-2-pyridin-2-yl-acetamide; N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetr ahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}-2-(1-oxypyridin-2-yl)acetamide ; N-hydroxy-3-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4 ,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzamidine; N-methoxy-3-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4 ,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzamidine; 1-(3-cyano-4-fluorophenyl-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-t etrahydro-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(3-aminomethyl-4-fluoro-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl] -4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 2-{7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tetr ahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzenesulfonamide; 2-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tet rahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzenesulfonamide; N-acetyl-2-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4, 5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzenesulfonamide; 1-(3-chloro-phenyl)-3-methanesulfonyl-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1 ,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 1-(3-chloro-phenyl)-3-methanesulfonyl-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]- 1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; 1-(3-chloro-phenyl)-3-(1-hydroxy-1-methyl-ethyl)-6-[4-(2-oxo-piperidin-1-yl )-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; and, 3-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tet rahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzamide; or a pharmaceutically acceptable salt form thereof.

9. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

10. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

11. A method according to claim 10, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

12. A method according to claim 10, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

13. A compound according to claim 8, wherein the compound is: 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl-4,5,6,7-tetrahyd ro-1H-pyrazole-[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt form thereof.

14. A compound according to claim 8, wherein the compound is: 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt form thereof.

15. A compound according to claim 8, wherein the compound is: 1-(4-methoxyphenyl)-3-(methylsulfonyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1, 4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one or a pharmaceutically acceptable salt form thereof.

16. A compound according to claim 8, wherein the compound is: 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahyd ro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt form thereof.

17. A compound according to claim 8, wherein the compound is: 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahy dro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt form thereof.

18. A compound according to claim 8, wherein the compound is: 1-(4-methoxyphenyl)-N,N-dimethyl-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt form thereof.

19. A compound according to claim 8, wherein the compound is: 3-(1-Hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1- yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one or a pharmaceutically acceptable salt form thereof.

20. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt form thereof.

21. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 3 or a pharmaceutically acceptable salt form thereof.

22. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

23. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt form thereof.

24. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 6 or a pharmaceutically acceptable salt form thereof.

25. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 7 or a pharmaceutically acceptable salt form thereof.

26. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 8 or a pharmaceutically acceptable salt form thereof.

27. A pharmaceutical composition, comprising; a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 13 or a pharmaceutically acceptable salt form thereof.

28. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 14 or a pharmaceutically acceptable salt form thereof.

29. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 15 or a pharmaceutically acceptable salt form thereof.

30. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 16 or a pharmaceutically acceptable salt form thereof.

31. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 17 or a pharmaceutically acceptable salt form thereof.

32. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 18 or a pharmaceutically acceptable salt form thereof.

33. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 19 or a pharmaceutically acceptable salt form thereof.

34. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt form thereof.

35. A method according to claim 34, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

36. A method according to claim 34, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

37. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 3 or a pharmaceutically acceptable salt form thereof.

38. A method according to claim 37, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

39. A method according to claim 37, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

40. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

41. A method according to claim 40, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

42. A method according to claim 40, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

43. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt form thereof.

44. A method according to claim 43, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

45. A method according to claim 43, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

46. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 6 or a pharmaceutically acceptable salt form thereof.

47. A method according to claim 46, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

48. A method according to claim 46, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism. kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

49. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 7 or a pharmaceutically acceptable salt form thereof.

50. A method according to claim 49, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

51. A method according to claim 49, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

52. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 8 or a pharmaceutically acceptable salt form thereof.

53. A method according to claim 52, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

54. A method according to claim 52, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

55. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 13 or a pharmaceutically acceptable salt form thereof.

56. A method according to claim 55, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

57. A method according to claim 55, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

58. A method according to claim 55, wherein the thromboembolic disorder is an acute coronary syndrome.

59. A method according to claim 55, wherein the thromboembolic disorder is stroke.

60. A method according to claim 55, wherein the thromboembolic disorder is deep vein thrombosis.

61. A method according to claim 55, wherein the thromboembolic disorder is pulmonary embolism.

62. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 14 or a pharmaceutically acceptable salt form thereof.

63. A method according to claim 62, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

64. A method according to claim 62, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

65. A method according to claim 62, wherein the thromboembolic disorder is an acute coronary syndrome.

66. A method according to claim 62, wherein the thromboembolic disorder is stroke.

67. A method according to claim 62, wherein the thromboembolic disorder is deep vein thrombosis.

68. A method according to claim 62, wherein the thromboembolic disorder is pulmonary embolism.

69. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 15 or a pharmaceutically acceptable salt form thereof.

70. A method according to claim 69, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

71. A method according to claim 69, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

72. A method according to claim 69, wherein the thromboembolic disorder is an acute coronary syndrome.

73. A method according to claim 69, wherein the thromboembolic disorder is stroke.

74. A method according to claim 69, wherein the thromboembolic disorder is deep vein thrombosis.

75. A method according to claim 69, wherein the thromboembolic disorder is pulmonary embolism.

76. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 16 or a pharmaceutically acceptable salt form thereof.

77. A method according to claim 76, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

78. A method according to claim 76, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial, embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass; (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

79. A method according to claim 76, wherein the thromboembolic disorder is an acute coronary syndrome.

80. A method according to claim 76, wherein the thromboembolic disorder is stroke.

81. A method according to claim 76, wherein the thromboembolic disorder is deep vein thrombosis.

82. A method according to claim 76, wherein the thromboembolic disorder is pulmonary embolism.

83. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 17 or a pharmaceutically acceptable salt form thereof.

84. A method according to claim 83, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

85. A method according to claim 83, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and Thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

86. A method according to claim 83, wherein the thromboembolic disorder is an acute coronary syndrome.

87. A method according to claim 83, wherein the thromboembolic disorder is stroke.

88. A method according to claim 83, wherein the thromboembolic disorder is deep vein thrombosis.

89. A method according to claim 83, wherein the thromboembolic disorder is pulmonary embolism.

90. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 18 or a pharmaceutically acceptable salt form thereof.

91. A method according to claim 90, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

92. A method according to claim 90, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

93. A method according to claim 90, wherein the thromboembolic disorder is an acute coronary syndrome.

94. A method according to claim 90, wherein the thromboembolic disorder is stroke.

95. A method according to claim 90, wherein the thromboembolic disorder is deep vein thrombosis.

96. A method according to claim 90, wherein the thromboembolic disorder is pulmonary embolism.

97. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 19 or a pharmaceutically acceptable salt form thereof.

98. A method according to claim 97, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

99. A method according to claim 97, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

100. A method according to claim 97, wherein the thromboembolic disorder is an acute coronary syndrome.

101. A method according to claim 97, wherein the thromboembolic disorder is stroke.

102. A method according to claim 97, wherein the thromboembolic disorder is deep vein thrombosis.

103. A method according to claim 97, wherein the thromboembolic disorder is pulmonary embolism.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc